Dx&Vx said Monday that it has agreed to establish various types of cooperation through partnering meetings with about 30 companies, including global pharmaceutical companies, drug developers, and investment companies at the 2024 JPMorgan Healthcare Conference and Biotech Showcase 2024 held in San Francisco, Calif.

At the partnership meeting, Dx&Vx held discussions with global pharma companies on introducing companion diagnostics and genetic information testing services for fetuses and newborns.

In meetings with new drug developers, the Korean company also decided to collaborate on biomarker discovery through genomic big data services and providing data necessary for new drug development.

Besides, the company examined various investment and technical cooperation, including licensing in and out for technologies expected to be synergistic with the pipeline developed by Dx&Vx, joint research, such as clinical trials, and introducing overseas drugs into Korea. It expects to sign full-fledged business agreements through detailed discussions.

At the Biotech Showcase, CEO Kwon Kyu-chan presented pipelines currently under development and plans to establish a companion diagnostic center in Italy. He also drew much attention to “Healthcare 4.0,” emphasized by Hanmi Pharmaceutical Chairman Lim Chong-yoon from global pharmaceutical and biotech companies, discussing collaboration plans.

"During these events, we held various partnering meetings across all business areas, from licensing to joint research to genome databases," Kwon said. "We will collaborate with global companies on technology and secure various business items to make 2024 a year of quantum jump in sales, too."